

FW

PTO/SB/21 (08-03)

Approved for use through 08/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/820,179	
	Filing Date	April 6, 2004	
	First Named Inventor	PAKULA, Andrew	
	Art Unit	To be determined	
	Examiner Name	To be determined	
Total Number of Pages in This Submission	5	Attorney Docket Number	ANP-00114.P.5.1


ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks 1. Form 1449A; 2. Form 1449B 3. 1 volume of references cited on Form 1449B; 4. Postcard		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	David R Preston Reg. No 88,710
Signature	
Date	June 30, 2004

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Raymond Wagenknecht
Signature	
Date	6/30/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 0.00

Complete if Known

Application Number	10/820,179
Filing Date	April 6, 2004
First Named Inventor	PAKULA, Andrew
Examiner Name	To be determined
Art Unit	To be determined
Attorney Docket No.	ANP-00114.P.5.1

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit
Account
Number
Deposit
Account
Name

501321

David R. Preston

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)					(\$) 0.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims		Extra Claims		Fee from below		Fee Paid
Independent	Multiple Dependent	-20** =	-3** =	X	X	

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 0.00

SUBMITTED BY

Name (Print/Type) David R. Preston

Signature

Registration No.
(Attorney/Agent)

38,710

(Complete if applicable)

Telephone 858-724-0375

Date

6/30/04

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Patent
Docket Number: ANP-00114.P.5.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	
)	
PAKULA, Andrew)	Examiner: To Be Determined
)	
Application No.: 10/820,179)	Art Unit: To Be Determined
)	
Filed: April 6, 2004)	
)	
For: A SCREENING METHOD FOR)	
IDENTIFYING LIGANDS FOR)	
TARGET PROTEINS)	

Commissioner for Patents
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant respectfully submits this information disclosure statement before the mailing of a First Office Action on the merits under 37 C.F.R. § 1.97(a)(3). Accordingly, no fee under 37 C.F.R. § 1.17(p) is deemed necessary.

Applicant submits herewith a listing of references on the attached Form 1449A and Form 1449B. Form 1449A includes a listing of references previously submitted in Parent U.S. Application Serial No. 09/904,186 or 08/978,381 or 08/547,889 or issued U.S. Patent No. 5,679,582. Form 1449B includes a listing of newly presented references.


Applicant submits 1 volume of references listed on the attached Form 1449B.

Information Disclosure Statement
ANP-00114.P.5.1
PAKULA, Andrew

Please apply any charges not covered, or any credits, to Deposit Account number 501321 in the name of David R. Preston & Associates, having Customer Number 24232.

Respectfully submitted,

Date: June 30, 2004


David R. Preston
Reg. No. 38,710

David R. Preston & Associates, APC
12625 High Bluff Drive
Suite 205
San Diego, CA 92130
phone: 858.724.0375
facsimile: 858.724.0384



INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form 1449A (Use several sheets if necessary)	Docket Number: ANP-00114.P.5.1	Application Number: 10/820,179
	Applicant: PAKULA, Andrew	
	Filing Date: April 6, 2004	Group Art Unit: 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	P1	5,325,295	06/1994	Fratantoni et al			
	P2						

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	Translation	
							YES	NO
	F1							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EXAMINER INITIALS		CITATION
	D1	Expert Report of James R. Broach on Issues of Patent Invalidity, Scriptgen Pharmaceuticals v. 3-Dimensional Pharmaceuticals, U.S. District Court, Delaware, Nov. 1 1999
	D2	Opening Brief in Support of Defendant's Motion for Summary Judgment of Invalidity, Scriptgen Pharmaceuticals v. 3-Dimensional Pharmaceuticals, U.S. District Court, Delaware, Jan 7, 2000
	D3	Scriptgen Pharmaceuticals' Answering Brief in Opposition to Defendant's Motion for Summary Judgment of Invalidity, Scriptgen Pharmaceuticals v. 3-Dimensional Pharmaceuticals, U.S. District Court, Delaware Feb 1, 2000
	D4	Bowie, Identifying Determinants of Folding and Activity for a Protein of Unknown Structure, B.A., Chemistry, Carleton College (1981), Submitted to the Department of Biology in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy at the Massachusetts Institute of Technology, May 1999

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EXAMINER INITIALS		CITATION
	D5	Fuller et al., "Drug Discovery at the Enzyme Level", Drug Discovery and Development, 177-189 (1987)
	D6	Crothers, D.M. Draft Opinion, Scriptgen Pharmaceuticals v. 3-Dimensional Pharmaceuticals, U.S. District Court, Delaware, pp. 1-15, Oct. 20, 1999
	D7	Horowitz et al., Memorandum Opinion, Scriptgen Pharmaceuticals v. 3-Dimensional Pharmaceuticals, U.S. District Court, Delaware, Dec. 15, 1999
	D8	Pakula A.A., "A Genetic and Biological Analysis of the Bacteriophage lambda Cro Protein, B.S. Biol and Chem., Tufts Univ (1980), Submitted to the Department of Biology in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy at the Massachusetts Institute of Technology, Sept 1988
	D9	Pantoliano, M.W. Senior Director, Biophysical Chemistry, 3-D Pharmaceuticals Inc., The ThermoFlour Strategy for High-Throughput Screening of Chemical Libraries against Therapeutic Targets Including Those Derived from Genomics" pp. 1-17
	D10	Alderman, E.M. Director, Pharmaceutical Research, New Ventures Zymak Corporation, "Abbreviating the Assay Development Process through Scaleable Automation Technology"
	D11	Wainer, I.W., Professor of Pharmacology, Georgetown University Medical Center, "Immobilized Receptor-Based Liquid Chromatographic Stationary Phases for Rapid On-Line Screening."
	D12	Little, J.N. Senior Vice President, Cetek Corporation, "A Powerful New Screening Technology Utilizing Capillary Electrophoresis"
	D13	Yeh, Li-An, Director Drug Discovery, NEN Life Science Products, "Development of a Novel Phospholipase C Assay in HTS: A Functional Assay for GPCR"
	D14	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form 1449B (Use several sheets if necessary)	Docket Number: ANP-00114.P.5.1	Application Number: 10/820,179
	Applicant: PAKULA, Andrew	
	Filing Date: April 6, 2004	Group Art Unit: 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	P1						

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	Translation	
							YES	NO
	F1							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EXAMINER INITIALS		CITATION
	D1	Tsai et al., Pharmaceutical Research 10:649-659 (1993)
	D2	Volkin et al., Harnessign Biotechnology for the 21 st Century: 298-302 (August 1992)
	D3	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--